Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVER-81: RVU120 plus venetoclax in relapsed/refractory acute myeloid leukemia after prior venetoclax plus hypomethylating agent failure
2023-505911-19-00Phase 2Authorised
- Sponsor
- Ryvu Therapeutics
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of rvu120 and venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by Ryvu Therapeutics. Primary endpoints: Incidence and severity of adverse events including dose-limiting toxicities and Complete remission rate. Planned start Jan 2024; status: authorised.
02
Drugs
rvu120venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505911-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505911-19-00.